What is the recommended duration of therapy for Prolia (denosumab) and Fosamax (alendronate)?

Duration of Therapy for Prolia (Denosumab) and Fosamax (Alendronate)

For Fosamax (alendronate): Use for 5 years initially, then consider a drug holiday in low-risk patients or continue up to 10 years in high-risk patients. For Prolia (denosumab): Continue indefinitely as long as fracture risk remains high, with reassessment at 5-10 years—drug holidays are NOT recommended due to severe rebound fracture risk.

Fosamax (Alendronate) Duration

Initial treatment duration is 5 years 1, 2. After this period, your decision depends on fracture risk stratification:

For Low-Risk Patients (After 5 Years):

• Consider a bisphosphonate holiday if:

  • T-score is greater than -2.5
  • Patient has remained fracture-free during treatment
  • No new risk factors have emerged 1

• Holiday duration: 3-5 years for oral alendronate 1

• During the holiday, reassess fracture risk every 2-4 years 3

For High to Very High-Risk Patients:

• Continue treatment up to 10 years total 1
• Very high-risk patients may continue for 6-10 years before considering a holiday 1

When to Resume After Holiday:

Restart alendronate if any of the following occur 3, 1:

• Significant BMD decline beyond the least significant change (LSC) of your DXA machine
• New fracture occurs
• Increase in bone turnover markers
• Other factors that increase clinical fracture risk

Critical caveat: The FDA label states "optimal duration of use has not been determined" and recommends considering discontinuation after 3-5 years for low-risk patients 2. This reflects the residual anti-fracture effect that bisphosphonates maintain even after stopping, as they remain incorporated in bone for years (terminal half-life exceeds 10 years) 2.

Prolia (Denosumab) Duration

Denosumab requires continuous, indefinite use—drug holidays are explicitly NOT recommended 3.

Standard Duration Approach:

• Reassess fracture risk after 5-10 years of treatment 3
• If fracture risk remains high: continue denosumab or transition to another osteoporosis therapy 3
• Evidence supports efficacy and safety up to 10 years of continuous treatment 3

Why No Drug Holidays?

The pharmacology of denosumab makes holidays dangerous 3:

1. Rapid reversibility: Effects completely reverse within 6 months if doses are delayed 3
2. Rebound phenomenon:
   • Bone turnover markers increase to or above baseline within 3-6 months of stopping 3
   • BMD declines 6.6% at lumbar spine and 5.3% at total hip within 12 months 3
   • BMD returns to pretreatment levels within 24 months 3
3. Multiple vertebral fractures: Risk of multiple vertebral fractures approaches 20% after discontinuation 4

If Denosumab Must Be Stopped:

You MUST transition to another antiresorptive immediately 3. Options include:

• Bisphosphonates (alendronate preferred)
• Hormone therapy
• Selective estrogen receptor modulators

Timing matters: Studies suggest alendronate administered 8 months (not 6 months) after the last denosumab dose is most effective at preventing BMD loss, and a second annual infusion is needed for continued benefit 3. One year of alendronate after 1 year of denosumab maintains BMD gains 5, though 2 years may provide additional stability 5.

Key Differences in Duration Strategy

Feature	Alendronate	Denosumab
Initial duration	5 years	5-10 years (reassess)
Maximum studied	10 years	10 years
Drug holiday	Yes, appropriate	NO—dangerous
Residual effect	Years (bone incorporation)	None (6 months)
Stopping safely	Can stop if low risk	Must transition to another drug

Common Pitfalls to Avoid

1. Never stop denosumab abruptly without transitioning to another antiresorptive—this is the single most important clinical point 3

2. Don't delay denosumab doses: Must be given every 6 months on schedule; even short delays trigger rebound 3

3. Don't assume bisphosphonate holidays apply to denosumab—the pharmacology is completely different 3, 1

4. Don't continue alendronate indefinitely without reassessment: Balance benefits against rare but serious risks (atypical femoral fractures, osteonecrosis of jaw) that increase with duration 3

5. Monitor during bisphosphonate holidays: Don't just stop and forget—reassess every 2-4 years 3, 1

The evidence strongly supports that bisphosphonates allow for strategic drug holidays due to their long skeletal retention, while denosumab's rapid reversibility makes continuous treatment or careful transition mandatory 3, 1, 3.